RT Journal Article
T1 Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.
A1 Casabonne, Delphine
A1 Benavente, Yolanda
A1 Seifert, Julia
A1 Costas, Laura
A1 Armesto, Maria
A1 Arestin, Maria
A1 Besson, Caroline
A1 Hosnijeh, Fatemeh S
A1 Duell, Eric J
A1 Weiderpass, Elisabete
A1 Masala, Giovanna
A1 Kaaks, Rudolf
A1 Canzian, Federico
A1 Chirlaque, Maria-Dolores
A1 Perduca, Vittorio
A1 Mancini, Francesca R
A1 Pala, Valeria
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 La Vecchia, Carlo
A1 Sanchez-Perez, Maria-Jose
A1 Tumino, Rosario
A1 Gunter, Marc J
A1 Amiano, Pilar
A1 Panico, Salvatore
A1 Sacerdote, Carlotta
A1 Schmidt, Julie A
A1 Boeing, Heiner
A1 Schulze, Matthias B
A1 Barricarte, Aurelio
A1 Riboli, Elio
A1 Olsen, Anja
A1 Tjønneland, Anne
A1 Vermeulen, Roel
A1 Nieters, Alexandra
A1 Lawrie, Charles H
A1 de Sanjose, Silvia
K1 chronic lymphocytic leukemia
K1 circulating miRNA
K1 prospective study
K1 serum
AB Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25-p75: 7-13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18-1.72), 1.64 (1.31-2.04) and 1.75 (1.31-2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve
PB John Wiley & Sons, Inc.
YR 2019
FD 2019-12-17
LK http://hdl.handle.net/10668/15036
UL http://hdl.handle.net/10668/15036
LA en
NO Casabonne D, Benavente Y, Seifert J, Costas L, Armesto M, Arestin M, et al. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. Int J Cancer. 2020 Sep 1;147(5):1315-1324.
DS RISalud
RD Apr 7, 2025